Heterocyclic Building Blocks-Tetrahydropyrans

1228779-96-1, 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

General procedure: To a solution of appropriate crude acid (1 eq) in CH2Cl2 wereadded EDCI (3 eq), DMAP (0.3 eq) and DIPEA (3 eq). The solutionwas stirred at room temperature for 0.5 h and compound 23 [7] (0.8eq) was added. The resulting mixture was stirred for another 8 hand water was added. The layers were separated, and the aqueouslayer was extracted with CH2Cl2. The combined organic layer waswashed with brine, dried over anhydrous Na2SO4, filtered, andconcentrated under vacuo. The residue was prified by chromatography(CH2Cl2/CH3OH 40:1) to provide target compounds 27a-i,28a-d and 34a-c., 1228779-96-1

The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Liu, Xiaohua; Zhang, Yu; Huang, Wenjing; Luo, Jia; Li, Yang; Tan, Wenfu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 159; (2018); p. 149 – 165;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

65412-03-5, 4-(2-Aminoethyl)tetrahydro-2H-pyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

0.081 g (0.62 mmol) of 2-(tetrahydro-2H-pyran-4-yl)ethanamine is added to a solution of 0.1 g (0.31 mmol) of the compound obtained in the previous step, in 3.1 ml of methanol. The reaction mixture is stirred at AT for 18 hours. The solvent is then evaporated off under reduced pressure and the residue obtained is purified by chromatography under silica (eluent: dichloromethane/methanol from 100/0 to 90/10). 0.081 g of expected compound is obtained., 65412-03-5

65412-03-5 4-(2-Aminoethyl)tetrahydro-2H-pyran 2773198, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; SANOFI; Pellet, Alain; US2013/245008; (2013); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110238-91-0,Methyl tetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.

Preparation 110; Tetrahydro-pyran-4-carboxylic acid amide; In a 5L flask, charge methyltetrahydropyran-4-carboxylate (500ml, 3. 75mol) and concentrated ammonium hydroxide (1.3L) and stir the reaction at room temperature for 48 hours. Filter the reaction and dry the white solid in a vacuum oven at 60¡ãC overnight. to obtained 36.33g white solid of the title compound., 110238-91-0

As the paragraph descriping shows that 110238-91-0 is playing an increasingly important role.

Reference£º
Patent; ELI LILLY AND COMPANY; WO2005/66126; (2005); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.693287-79-5,tert-Butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate,as a common compound, the synthetic route is as follows.

693287-79-5, Example 63 Synthesis of 3-Ethyl-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridine A mixture of tert-butyl 2-(tetrahydro-2H-pyran-4-yl)hydrazinecarboxylate (3.8 g, 0.018 mol) and trifluoroacetic acid (20 mL, 0.3 mol) were stirred in dichloromethane (20 mL) for 90 minutes. The mixture was concentrated, and the residue was taken up in acetonitrile (30 mL). 1-(2,6-difluoropyridin-3-yl)propan-1-one (2.34 g, 0.0137 mol, prepared as described above in Example 62) was then added, and the resulting mixture was stirred at 75 C. for 72 hr. After cooling to room temperature, the mixture was concentrated, and the residue was purified by flash chromatography on silica gel using a 10-50% hexane:ethyl acetate gradient (flow rate 20 mL/min). The organics were combined and the crude product was then extracted with ethyl acetate. The combined extracts were washed with saturated sodium bicarbonate and then concentrated to afford 2.86 g (83.9%) of 3-ethyl-6-fluoro-1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazolo[3,4-b]pyridine as a white solid. LC/MS (EI) tR 3.5 (Method E), m/z 250 (M++1).

The synthetic route of 693287-79-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; Dunn, Robert F.; Kuester, Eric Mikal; Conticello, Richard D.; Hopper, Allen T.; US2007/254913; (2007); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

141095-78-5, 2-Bromo-1-(tetrahydro-2H-pyran-4-yl)ethanone is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

To a mixture of 2-mercapto-4,6-dimethylnicotinonitrile (50 mg, 0.30 mmol, 1 equivalent) in isopropyl alcohol (2 mL) was added 2-bromo-l-(tetrahydro-2H-pyran-4-yl)ethan- 1-one (0.045 mL, 0.37 mmol, 1.2 equivalent) and 10% potassium hydroxide (0.28 mL). After 10 minutes, the reaction was concentrated in vacuo. Purification by reverse phase HPLC afforded 32 mg (37%) of the title compound. 1H NMR (400 MHz, OMSO-d6) delta 7.76 (s, 2H), 7.08 (s, 1H), 3.92 (d, J= 11.1 Hz, 2H), 3.45 (ddd, J= 11.0, 11.2, 3.0 Hz, 2H), 2.97-2.91 (m, 1H), 2.72 (s, 3H), 2.52 (s, 3H), 1.72-1.66 (m, 4H); ES-MS [M+l]+: 291.2., 141095-78-5

The synthetic route of 141095-78-5 has been constantly updated, and we look forward to future research findings.

Reference£º
Patent; VANDERBILT UNIVERSITY; LINDSLEY, Craig W.; ENGERS, Darren W.; CONN, P. Jeffrey; BOLLINGER, Katrina A.; CAPSTICK, Rory; SPEARING, Paul; BOLLINGER, Sean R.; (72 pag.)WO2018/85808; (2018); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

General procedure: To a solution of appropriate crude acid (1 eq) in CH2Cl2 wereadded EDCI (3 eq), DMAP (0.3 eq) and DIPEA (3 eq). The solutionwas stirred at room temperature for 0.5 h and compound 23 [7] (0.8eq) was added. The resulting mixture was stirred for another 8 hand water was added. The layers were separated, and the aqueouslayer was extracted with CH2Cl2. The combined organic layer waswashed with brine, dried over anhydrous Na2SO4, filtered, andconcentrated under vacuo. The residue was prified by chromatography(CH2Cl2/CH3OH 40:1) to provide target compounds 27a-i,28a-d and 34a-c.

1228779-96-1, The synthetic route of 1228779-96-1 has been constantly updated, and we look forward to future research findings.

Reference£º
Article; Liu, Xiaohua; Zhang, Yu; Huang, Wenjing; Luo, Jia; Li, Yang; Tan, Wenfu; Zhang, Ao; European Journal of Medicinal Chemistry; vol. 159; (2018); p. 149 – 165;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

Into a 250-mL round-bottom flask, was placed 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l-yl]methyl]piperazin-l-yl)-2-[(l2R)- l2-methyl-l3-oxa-2,4,l0-triazatricyclo[7.4.0.0A[3,7]]trideca-l(9),2,5,7-tetraen-l0-yl]benzoic acid (1.6 g, 1 equiv), DCM (20 mL), 3-nitro-4-[[(oxan-4-yl)methyl]amino]benzene-l- sulfonamide (890 mg, 1.2 equiv), DMAP (1.25 g, 4 equiv), EDCI (980 mg, 2 equiv). The resulting solution was stirred for 14 hr at room temperature. The resulting mixture was concentrated. The residue was applied onto a silica gel column with EA/DCM (1/10). This resulted in 0.82 g of 4-(4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohex-l-en-l- yl]methyl]piperazin-l-yl)-2-[(l2R)-l2-methyl-l3-oxa-2,4,l0- triazatricyclo[7.4.0.0A[3,7]]trideca-l(9),2,5,7-tetraen-l0-yl]-N-(3-nitro-4-[[(oxan-4- yl)methyl]amino]benzenesulfonyl)benzamide as a yellow solid. LC-MS (ES, m/z): 923 [M+l]+; RT = 3.50 min. 1H NMR (300 MHz, CDCl3, ppm): d 12.48 (s, 1H), 8.62 (d, / = 2.4 Hz, 2H), 8.54-8.38 (m, 1H), 8.16-7.95 (m, 1H), 7.81-7.71 (m, 1H), 7.32-7.12 (m, 6H), 7.07 (t, J = 2.9 Hz, 1H), 6.97-6.77 (m, 3H), 6.76-6.60 (m, 2H), 6.52 (s, 1H), 6.09 (d, J = 3.0 Hz, 1H), 4.88 (d, J = 7.7 Hz, 1H), 4.02 (dd, J = 11.8, 4.2 Hz, 2H), 3.55-3.34 (m, 4H), 3.32-3.14 (m, 5H), 3.08 (s, 1H), 2.77 (d, J = 9.6 Hz, 2H), 2.28 (s, 3H), 2.19 (s, 2H), 1.99 (d, / = 7.6 Hz, 4H), 1.72 (d, / = 12.7 Hz, 2H), 1.45 (ddd, / = 24.5, 12.3, 5.8 Hz, 6H), 0.94 (d, / = 2.1 Hz, 6H)., 1228779-96-1

1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; NEWAVE PHARMACEUTICAL INC.; CHEN, Yi; (475 pag.)WO2020/41406; (2020); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

4677-20-7, 4-(2-Bromoethyl)tetrahydropyran is a Tetrahydropyrans compound, ?involved in a variety of chemical synthesis. Rlated chemical reaction is continuously updated

Example 7: 6-Amino-2-butylamino-9-r2-(tetrahvdro-2H-pyran-4-yl)ethyll-7,9-dihvdro- 8H-purin-8-one To a solution of /V2-butyl-8-methoxy-9H-purine-2,6-diamine trifluoroacetic acid salt (100 mg) in dry N,N-dimethylformamide (1 ml) at room temperature and under nitrogen was added potassium carbonate (158 mg) in one go. The reaction was stirred at 6O C for 1.5 hours and then cooled to 5O C. A solution of 4-(2- bromoethyl)tetrahydro-2H-pyran (60 mg) in dry N,N-dimethylformamide (0.5 ml) was added in one go and the reaction heated at 5O C overnight. The reaction was diluted with ethyl acetate (15 ml) and washed with water (5 ml). The organic layer was separated and concentrated in vacuo. The product was purified by C18 reverse phase chromatography using water (0.1% formic acid)-acetonitrile (0.05% formic acid) as eluant (20-60%) to afford a yellow viscous oil (47mg) that was dissolved in dry methanol (4 ml) at room temperature and under nitrogen was added 4.0M hydrogen chloride in 1 ,4-dioxane (0.8 ml) in one go. The reaction was left to stir at room temperature overnight. The reaction was neutralised by the addition of 2.0M sodium hydroxide solution and concentrated in vacuo. The residue was taken up in water (5 ml) and the solid filtered and dried in vacuo (60C) for 30 minutes. This afforded the title compound as a beige solid (23mg). MS calcd for (C16H26N6O2)+ = 334 MS found (electrospray): (M+H)+ =3351H NMR ((CDa)2SO): delta 9.78 (1 H, s), 6.08-6.21 (3H, br. s), 3.80 (2H, m), 3.65 (2H, t), 3.21 (2H, m), 3.16 (2H, m), 1.66 (2H, m), 1.57 (2H, m), 1.36-1.49 (3H, m), 1.29 (2H, m), 1.13 (2H, m), 0.88 (3H, t)., 4677-20-7

As the paragraph descriping shows that 4677-20-7 is playing an increasingly important role.

Reference£º
Patent; SMITHKLINE BEECHAM CORPORATION; WO2008/101867; (2008); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.1228779-96-1,3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide,as a common compound, the synthetic route is as follows.

The mixture of (cis-or trans-) 2- ((1H-pyrrolo [2, 3-b] pyridin-5-yl) oxy)-4-(4- (2- (2-chlorophenyl) pyrrolidin-1-yl) cyclohexyl) benzoic acid (142 mg, 0.28 mmol; product of step 6), triethylamine (85 mg, 0.84 mmol), 2- (7-azabenzotriazol-1-yl) -N, N, N’, N’-tetramethyluronium hexafluorophosphate (125 mg, 0.33 mmol) in DCM (20 mL) was stirred for 2 hours. To the resulting reaction were added 3-nitro-4- (((tetrahydro-2H-pyran-4-yl) methyl) amino) benzenesulfonamide (104 mg, 0.33 mmol) and DMAP (3 mg, 0.03 mmol) and stirred overnight. The reaction mixture was concentrated in vacuum and purified by chromatography column on silica (eluent: PE/EA = 1/1 to DCM/MeOH = 10/1) to afford a crude product, which was purified with Pre-TLC (DCM/MeOH, 25/1) to give the product Example D1a (17.5 mg, 7.71%). 1H NMR (400 MHz, DMSO-d 6) delta ppm: 12.16 (br, 1H), 11.78 (br, 1H), 8.61 (m, 2H), 8.05 (s, 1H), 7.85 (d, J = 8.0 Hz, 1H), 7.63 (s, 1H), 7.55 (m, 1H), 7.51 (d, J = 8.0 Hz, 1H), 7.45 (d, J = 8.0 Hz, 1H), 7.27 (d, J = 8.0 Hz, 1H), 7.16 (d, J = 8.0 Hz, 1H), 7.00 (t, J = 8.0 Hz, 1H), 6.94 (d, J = 8.0 Hz, 1H), 6.86 (t, J = 8.0 Hz, 1H), 6.51 (s, 1H), 6.44 (s, 1H), 4.10 (d, J = 8.0 Hz, 1H), 3.85 (d, J = 8.0 Hz, 2H), 3.30-3.23 (m, 5H), 3.16-3.10-3.04 (m, 2H), 2.67-2.55 (m, 1H), 2.42-2.33 (m, 3H), 2.13-1.99 (m, 2H), 1.87-1.82 (m, 2H), 1.67-1.58 (m, 4H), 1.41-1.26 (m, 6H). MS (ESI, m/e) [M+1] + 813.2.

1228779-96-1, 1228779-96-1 3-Nitro-4-(((tetrahydro-2H-pyran-4-yl)methyl)amino)benzenesulfonamide 57474953, aTetrahydropyrans compound, is more and more widely used in various fields.

Reference£º
Patent; BEIGENE, LTD.; GUO, Yunhang; XUE, Hai; WANG, Zhiwei; SUN, Hanzi; (493 pag.)WO2019/210828; (2019); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics

With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.110238-91-0,Methyl tetrahydro-2H-pyran-4-carboxylate,as a common compound, the synthetic route is as follows.

A solution of methyl tetrahydro-2H-pyran-4-carboxylate (5 g, 34.6 mmol) in anhydrous diethyl ether was chilled in an ice bath and 1 M LiAlH4 in diethyl ether (52 mL, 51.9 mmol) was added dropwise under an N2 atmosphere. The reaction was allowed to warm to room temperature with stirring overnight. The reaction was quenched by slowly adding 1 N aqueous NaOH (3 mL). The slurry was filtered through a pad of Celite. The Celite pad was rinsed with diethyl ether followed by methanol and the solution was dried in vacuo to yield (tetrahydro-2H- pyran-4-yl)methanol (4 g, 34.6 mmol) as a clear oil. [M+eta] calc’d for C6H]2O2, 117; found, 117., 110238-91-0

As the paragraph descriping shows that 110238-91-0 is playing an increasingly important role.

Reference£º
Patent; TAKEDA PHARMACEUTICAL COMPANY LIMITED; WO2009/97578; (2009); A1;,
Tetrahydropyran – Wikipedia
Tetrahydropyran – an overview | ScienceDirect Topics